We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

118 hedge funds and large institutions have $521M invested in Xenon Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

36% more call options, than puts

Call options by funds: $30.4M | Put options by funds: $22.3M

17% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 30

15% more funds holding

Funds holding: 103 → 118 (+15)

0.99% more ownership

Funds ownership: 81.94% → 82.93% (+0.99%)

22% less capital invested

Capital invested by funds: $671M → $521M (-$150M)

67% less funds holding in top 10

Funds holding in top 10: 6 → 2 (-4)

Holders
118
Holders Change
+15
Holders Change %
+14.56%
% of All Funds
2.07%
Holding in Top 10
2
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-66.67%
% of All Funds
0.04%
New
25
Increased
35
Reduced
30
Closed
9
Calls
$30.4M
Puts
$22.3M
Net Calls
+$8.06M
Net Calls Change
+$4.85M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$12.2M
2
DCM
Driehaus Capital Management
Illinois
+$9.84M
3
SCM
Suvretta Capital Management
New York
+$9.82M
4
PA
Perceptive Advisors
New York
+$5.96M
5
TLP
Tri Locum Partners
New York
+$4.59M

Top Sellers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
-$27.7M
2
O
OrbiMed
New York
-$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.08M
4
UBS AM
UBS AM
Illinois
-$5.94M
5
IC
Ikarian Capital
Texas
-$4.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lord, Abbett & Co
26
Lord, Abbett & Co
New Jersey
$5.78M -$111K -6,367 -2%
IC
27
Ikarian Capital
Texas
$5.77M -$4.57M -263,168 -41%
SFM
28
Sphera Funds Management
Israel
$5.71M +$1.69M +97,380 +35%
MWNA
29
Marshall Wace North America
New York
$5.17M -$1.27M -72,958 -18%
PHP
30
Parkman Healthcare Partners
Connecticut
$4.75M -$1.56M -90,000 -22%
TLP
31
Tri Locum Partners
New York
$4.04M +$4.59M +264,134 New
AllianceBernstein
32
AllianceBernstein
Tennessee
$4.02M +$4.23M +243,195 +1,222%
Millennium Management
33
Millennium Management
New York
$3.61M -$1.14M -65,529 -22%
ACM
34
Altium Capital Management
New York
$3.3M +$1.06M +61,000 +39%
SCM
35
Soleus Capital Management
Connecticut
$3.3M -$313K -18,000 -8%
WP
36
Woodline Partners
California
$3.06M +$3.48M +199,984 New
NFGH
37
Nan Fung Group Holdings
Hong Kong
$3.02M – – –
MIM
38
Monashee Investment Management
Massachusetts
$2.75M +$3.13M +180,000 New
Two Sigma Advisers
39
Two Sigma Advisers
New York
$2.69M +$1.61M +92,800 +112%
AGA
40
Altrinsic Global Advisors
Connecticut
$2.6M – – –
Two Sigma Investments
41
Two Sigma Investments
New York
$2.59M +$1.47M +84,458 +99%
TCM
42
Tekla Capital Management
Massachusetts
$2.58M – – –
Axa
43
Axa
France
$2.44M +$2.77M +159,643 New
Dimensional Fund Advisors
44
Dimensional Fund Advisors
Texas
$2.31M +$2.37M +136,187 +907%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$2.27M -$264K -15,192 -9%
State Street
46
State Street
Massachusetts
$2.25M +$293K +16,852 +13%
SSA
47
Schonfeld Strategic Advisors
New York
$1.84M +$409K +23,521 +24%
Vanguard Group
48
Vanguard Group
Pennsylvania
$1.64M +$65.3K +3,756 +4%
FAM
49
Fred Alger Management
New York
$1.62M +$1.84M +105,989 New
Goldman Sachs
50
Goldman Sachs
New York
$1.47M -$977K -56,233 -37%
1
2
3 4 5

XENE Hedge Fund Activity: Q3 2021 in Review

118 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2021, worth a combined $521M — down 22% from $671M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new XENE positions and 9 closed out — a net gain of 16 holders — while 35 added to existing stakes and 30 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $12.2M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $27.7M sold.

  • 118 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2021, up from 103 in Q2 2021.
  • Funds reported $521M of Xenon Pharmaceuticals stock for Q3 2021, down 22% quarter-over-quarter.
  • 25 funds opened new Xenon Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of +16 holders.
  • The largest Xenon Pharmaceuticals buyer in Q3 2021 was Great Point Partners, an estimated $12.2M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2021 was Eventide Asset Management, an estimated $27.7M sold.

Based on aggregated 13F filings for Q3 2021.